Associated Genetic Biomarkers
HRAS G12D is present in 0.05% of AACR GENIE cases, with bladder urothelial carcinoma, cutaneous melanoma, infiltrating renal pelvis and ureter urothelial carcinoma, melanoma, and colorectal adenocarcinoma having the greatest prevalence .
HRAS G12D serves as an inclusion eligibility criterion in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains HRAS G12D as an inclusion criterion, 1 is phase 1/phase 2 (0 open).
Trials with HRAS G12D in the inclusion eligibility criteria most commonly target malignant solid tumor .
Aldesleukin, anti-k-ras g12d mtcr-transduced autologous peripheral blood lymphocytes, cyclophosphamide, and fludarabine are the most frequent therapies in trials with HRAS G12D as an inclusion criteria .
Significance of HRAS G12D in Diseases
Malignant Solid Tumor +
HRAS is altered in 1.02% of malignant solid tumor patients with HRAS G12D present in 0.04% of all malignant solid tumor patients .
HRAS G12D is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains HRAS G12D and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.